What is Opko Health's earnings per share (EPS)?

Opko Health (OPK) reported diluted earnings per share of $-0.30 for fiscal year 2025. This represents a -275.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Opko Health Financials

OPK

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Opko Health (OPK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 31/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Opko Health has an operating margin of -19.4%, meaning the company retains $-19 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -21.3% the prior year.

Growth

Opko Health's revenue declined 14.9% year-over-year, from $713.1M to $606.9M. This contraction results in a growth score of 8/100.

Leverage

100

Opko Health carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.97, Opko Health holds $3.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

While Opko Health generated -$178.5M in operating cash flow, capex of $12.3M consumed most of it, leaving -$190.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Opko Health generates a -17.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -3.9% the prior year.

Piotroski F-Score Neutral

4/9

Opko Health passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.79x

For every $1 of reported earnings, Opko Health generates $0.79 in operating cash flow (-$178.5M OCF vs -$225.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$606.9M

YoY-14.9%

5Y CAGR-15.8%

10Y CAGR+7.1%

Opko Health generated $606.9M in revenue in fiscal year 2025. This represents a decrease of 14.9% from the prior year.

EBITDA

-$25.8M

YoY+52.2%

Opko Health's EBITDA was -$25.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.2% from the prior year.

Net Income

-$225.7M

YoY-324.0%

Opko Health reported -$225.7M in net income in fiscal year 2025. This represents a decrease of 324.0% from the prior year.

EPS (Diluted)

$-0.30

YoY-275.0%

Opko Health earned $-0.30 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 275.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$190.8M

YoY+8.5%

Opko Health generated -$190.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 8.5% from the prior year.

Cash & Debt

$364.4M

YoY-14.6%

5Y CAGR+38.2%

10Y CAGR+6.5%

Opko Health held $364.4M in cash against $2.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

759M

YoY+13.0%

5Y CAGR+2.5%

Opko Health had 759M shares outstanding in fiscal year 2025. This represents an increase of 13.0% from the prior year.

Margins & Returns

Gross Margin

33.9%

YoY+3.3pp

10Y CAGR-2.8pp

Opko Health's gross margin was 33.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the prior year.

Operating Margin

-19.4%

YoY+2.0pp

5Y CAGR-23.4pp

10Y CAGR+20.2pp

Opko Health's operating margin was -19.4% in fiscal year 2025, reflecting core business profitability. This is up 2.0 percentage points from the prior year.

Net Margin

-37.2%

YoY-29.7pp

5Y CAGR-39.3pp

10Y CAGR-20.1pp

Opko Health's net profit margin was -37.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 29.7 percentage points from the prior year.

Return on Equity

-17.8%

YoY-13.9pp

5Y CAGR-19.6pp

10Y CAGR-15.2pp

Opko Health's ROE was -17.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 13.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$124.0M

YoY+17.9%

5Y CAGR+10.5%

10Y CAGR+2.0%

Opko Health invested $124.0M in research and development in fiscal year 2025. This represents an increase of 17.9% from the prior year.

Share Buybacks

$47.0M

YoY-47.9%

Opko Health spent $47.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 47.9% from the prior year.

Capital Expenditures

$12.3M

YoY-50.9%

5Y CAGR-18.3%

10Y CAGR+1.2%

Opko Health invested $12.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 50.9% from the prior year.

OPK Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$606.9M-14.9%	$713.1M-17.4%	$863.5M-14.0%	$1.0B-43.4%	$1.8B+23.6%	$1.4B
Cost of Revenue	$400.9M-18.9%	$494.6M-9.3%	$545.4M-23.8%	$716.0M	N/A	N/A
Gross Profit	$205.9M-5.8%	$218.5M-31.3%	$318.1M+10.4%	$288.2M	N/A	N/A
R&D Expenses	$124.0M+17.9%	$105.2M+17.4%	$89.6M+21.3%	$73.9M-3.9%	$76.8M+2.0%	$75.3M
SG&A Expenses	$223.0M-26.7%	$304.2M+1.2%	$300.6M-19.4%	$372.7M-20.5%	$468.9M+31.9%	$355.6M
Operating Income	-$117.4M+22.8%	-$152.1M+3.2%	-$157.0M+30.6%	-$226.3M-1306.7%	$18.8M-67.5%	$57.7M
Interest Expense	$0-100.0%	$47.5M+251.4%	$13.5M+12.0%	$12.1M-36.1%	$18.9M	N/A
Income Tax	-$15.7M-136.7%	$42.8M+865.6%	$4.4M+107.0%	-$63.5M-510.0%	$15.5M-12.1%	$17.6M
Net Income	-$225.7M-324.0%	-$53.2M+71.8%	-$188.9M+42.5%	-$328.4M-989.5%	-$30.1M-198.6%	$30.6M
EPS (Diluted)	$-0.30-275.0%	$-0.08+68.0%	$-0.25+45.7%	$-0.46-820.0%	$-0.05-200.0%	$0.05

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$148.5M-2.1%	$151.7M-3.3%	$156.8M+4.6%	$150.0M-18.3%	$183.6M+5.8%	$173.6M-4.7%	$182.2M+4.9%	$173.7M
Cost of Revenue	N/A	$101.8M-5.2%	$107.4M+0.1%	$107.3M	N/A	$133.5M+2.3%	$130.5M-0.8%	$131.6M
Gross Profit	N/A	$49.9M+1.0%	$49.4M+15.9%	$42.6M	N/A	$40.1M-22.3%	$51.7M+22.8%	$42.1M
R&D Expenses	N/A	$30.1M-0.9%	$30.3M-1.6%	$30.8M	N/A	$28.8M+19.5%	$24.1M+9.8%	$21.9M
SG&A Expenses	N/A	$53.8M-9.7%	$59.6M+0.9%	$59.1M	N/A	$98.2M+42.7%	$68.8M-1.9%	$70.2M
Operating Income	N/A	$48.1M+180.1%	-$60.0M+10.7%	-$67.2M	N/A	$14.2M+123.1%	-$61.7M+13.7%	-$71.5M
Interest Expense	N/A	$11.4M-83.8%	$70.3M+354.7%	$15.5M	N/A	$17.4M+112.2%	$8.2M+6.4%	$7.7M
Income Tax	N/A	$19.8M+240.6%	-$14.1M-144.0%	-$5.8M	N/A	$23.5M+8502.5%	-$280K+79.3%	-$1.4M
Net Income	-$31.3M-244.5%	$21.6M+114.6%	-$148.4M-119.5%	-$67.6M-582.0%	$14.0M-43.6%	$24.9M+341.5%	-$10.3M+87.4%	-$81.8M
EPS (Diluted)	$-0.04-233.3%	$0.03+115.8%	$-0.19-90.0%	$-0.10-1100.0%	$0.01-66.7%	$0.03+400.0%	$-0.01+91.7%	$-0.12

OPK Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.9B-12.2%	$2.2B+9.4%	$2.0B-7.2%	$2.2B-9.7%	$2.4B-3.0%	$2.5B
Current Assets	$581.9M-12.1%	$662.1M+113.9%	$309.5M-21.6%	$394.5M-52.1%	$823.0M+57.3%	$523.2M
Cash & Equivalents	$364.4M-14.6%	$426.6M+344.9%	$95.9M-37.4%	$153.2M+13.7%	$134.7M+86.6%	$72.2M
Inventory	$65.8M+15.9%	$56.8M-13.5%	$65.7M-11.3%	$74.1M-14.4%	$86.5M-34.6%	$132.3M
Accounts Receivable	$90.3M-23.5%	$118.0M-4.3%	$123.4M-3.1%	$127.3M-51.0%	$259.6M-9.3%	$286.3M
Goodwill	$484.3M-8.5%	$529.3M-11.5%	$598.3M+0.4%	$595.9M+14.5%	$520.6M-23.5%	$680.6M
Total Liabilities	$664.0M-20.5%	$834.8M+34.1%	$622.5M+2.8%	$605.6M-15.3%	$714.6M-10.8%	$801.5M
Current Liabilities	$146.7M-24.0%	$193.1M-3.5%	$200.1M-6.3%	$213.5M-35.3%	$330.0M-12.1%	$375.5M
Long-Term Debt	$2.3M-24.7%	$3.0M-61.1%	$7.7M-16.8%	$9.3M-95.5%	$205.3M+5249.8%	$3.8M
Total Equity	$1.3B-7.1%	$1.4B-1.7%	$1.4B-11.0%	$1.6B-7.3%	$1.7B+0.8%	$1.7B
Retained Earnings	-$2.3B-10.9%	-$2.1B-2.6%	-$2.0B-10.4%	-$1.8B-20.6%	-$1.5B-2.0%	-$1.5B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.9B-3.2%	$2.0B+1.1%	$2.0B-7.3%	$2.1B-3.3%	$2.2B-2.5%	$2.3B+14.0%	$2.0B+0.3%	$2.0B
Current Assets	$581.9M-7.2%	$627.1M+7.5%	$583.3M-20.9%	$737.6M+11.4%	$662.1M+5.2%	$629.6M+75.9%	$358.0M-8.5%	$391.3M
Cash & Equivalents	$364.4M-11.5%	$412.0M+54.1%	$267.3M-37.7%	$428.8M+0.5%	$426.6M+6.6%	$400.1M+886.0%	$40.6M-46.4%	$75.6M
Inventory	$65.8M+1.3%	$65.0M-2.1%	$66.3M+3.7%	$64.0M+12.7%	$56.8M-4.4%	$59.4M-1.2%	$60.2M+1.3%	$59.4M
Accounts Receivable	$90.3M-4.6%	$94.6M-4.8%	$99.4M+3.4%	$96.2M-18.5%	$118.0M+10.7%	$106.6M+1.2%	$105.3M-5.4%	$111.4M
Goodwill	$484.3M+0.1%	$484.0M0.0%	$484.2M+1.6%	$476.7M-9.9%	$529.3M-1.2%	$535.9M+1.1%	$530.1M-0.1%	$530.6M
Total Liabilities	$664.0M-3.8%	$690.0M+2.1%	$676.1M-17.2%	$816.7M-2.2%	$834.8M-2.1%	$852.7M+45.9%	$584.6M-18.9%	$721.2M
Current Liabilities	$146.7M-13.4%	$169.3M-1.1%	$171.2M-42.1%	$295.9M+53.2%	$193.1M-8.8%	$211.7M-3.6%	$219.6M+7.4%	$204.3M
Long-Term Debt	$2.3M-9.8%	$2.5M-9.5%	$2.8M-2.1%	$2.8M-5.6%	$3.0M-14.9%	$3.5M-4.0%	$3.7M-8.9%	$4.0M
Total Equity	$1.3B-2.9%	$1.3B+0.7%	$1.3B-1.1%	$1.3B-3.9%	$1.4B-2.7%	$1.4B+0.6%	$1.4B+11.4%	$1.3B
Retained Earnings	-$2.3B-1.4%	-$2.3B+0.9%	-$2.3B-7.0%	-$2.1B-3.3%	-$2.1B+0.7%	-$2.1B+1.2%	-$2.1B-0.5%	-$2.1B

OPK Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$178.5M+2.7%	-$183.5M-550.7%	-$28.2M+70.4%	-$95.2M-348.3%	$38.3M-2.9%	$39.5M
Capital Expenditures	$12.3M-50.9%	$25.0M+53.7%	$16.3M-33.8%	$24.6M-23.6%	$32.2M-4.5%	$33.7M
Free Cash Flow	-$190.8M+8.5%	-$208.5M-368.8%	-$44.5M+62.9%	-$119.8M-2037.7%	$6.2M+6.7%	$5.8M
Investing Cash Flow	$230.3M-34.6%	$352.2M+2035.5%	-$18.2M-120.0%	$91.0M+153.2%	$35.9M+296.2%	-$18.3M
Financing Cash Flow	-$118.1M-164.1%	$184.2M+1729.4%	-$11.3M-149.2%	$23.0M+321.9%	-$10.3M+70.5%	-$35.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$47.0M-47.9%	$90.2M	$0	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$25.9M+25.2%	-$34.6M+58.5%	-$83.4M-141.4%	-$34.6M+22.2%	-$44.4M+42.4%	-$77.1M-191.6%	-$26.4M+25.7%	-$35.6M
Capital Expenditures	$2.7M-15.0%	$3.1M-4.5%	$3.3M+2.8%	$3.2M-41.0%	$5.4M-31.8%	$7.9M+10.0%	$7.2M+62.4%	$4.4M
Free Cash Flow	-$28.6M+24.3%	-$37.8M+56.4%	-$86.7M-129.7%	-$37.7M+24.2%	-$49.8M+41.4%	-$85.0M-152.6%	-$33.7M+15.9%	-$40.0M
Investing Cash Flow	-$2.0M-101.1%	$194.6M+6968.3%	-$2.8M-107.0%	$40.5M-65.1%	$116.0M-53.2%	$247.8M+3559.7%	-$7.2M-63.0%	-$4.4M
Financing Cash Flow	-$18.3M-13.2%	-$16.2M+79.6%	-$79.5M-1876.4%	-$4.0M+90.1%	-$40.5M-119.6%	$206.1M+9846.6%	-$2.1M-110.3%	$20.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$13.5M-11.6%	$15.3M-16.3%	$18.3M	$0-100.0%	$16.5M-30.7%	$23.8M	$0-100.0%	$50.0M

OPK Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	33.9%+3.3pp	30.6%-6.2pp	36.8%+8.1pp	28.7%	N/A	N/A
Operating Margin	-19.4%+2.0pp	-21.3%-3.1pp	-18.2%+4.4pp	-22.5%-23.6pp	1.1%-3.0pp	4.0%
Net Margin	-37.2%-29.7pp	-7.5%+14.4pp	-21.9%+10.8pp	-32.7%-31.0pp	-1.7%-3.8pp	2.1%
Return on Equity	-17.8%-13.9pp	-3.9%+9.7pp	-13.6%+7.4pp	-21.0%-19.2pp	-1.8%-3.6pp	1.8%
Return on Assets	-11.7%-9.3pp	-2.4%+7.0pp	-9.4%+5.8pp	-15.2%-13.9pp	-1.3%-2.5pp	1.2%
Current Ratio	3.97+0.5	3.43+1.9	1.55-0.3	1.85-0.6	2.49+1.1	1.39
Debt-to-Equity	0.000.0	0.000.0	0.010.0	0.01-0.1	0.12+0.1	0.00
FCF Margin	-31.4%-2.2pp	-29.2%-24.1pp	-5.1%+6.8pp	-11.9%-12.3pp	0.4%-0.1pp	0.4%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	32.9%+1.4pp	31.5%+3.1pp	28.4%	N/A	23.1%-5.2pp	28.3%+4.1pp	24.2%
Operating Margin	N/A	31.7%+69.9pp	-38.3%+6.5pp	-44.8%	N/A	8.2%+42.0pp	-33.9%+7.3pp	-41.1%
Net Margin	-21.1%-35.3pp	14.3%+108.9pp	-94.7%-49.6pp	-45.1%-52.7pp	7.6%-6.7pp	14.3%+20.0pp	-5.7%+41.5pp	-47.1%
Return on Equity	-2.5%-4.1pp	1.7%+13.1pp	-11.5%-6.3pp	-5.1%-6.2pp	1.0%-0.7pp	1.8%+2.5pp	-0.7%+5.8pp	-6.5%
Return on Assets	-1.6%-2.7pp	1.1%+8.6pp	-7.5%-4.3pp	-3.2%-3.8pp	0.6%-0.5pp	1.1%+1.6pp	-0.5%+3.6pp	-4.2%
Current Ratio	3.97+0.3	3.70+0.3	3.41+0.9	2.49-0.9	3.43+0.5	2.97+1.3	1.63-0.3	1.92
Debt-to-Equity	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	-19.3%+5.6pp	-24.9%+30.4pp	-55.3%-30.1pp	-25.2%+2.0pp	-27.1%+21.8pp	-49.0%-30.5pp	-18.5%+4.6pp	-23.0%

Similar Companies

Neogen Corp NEOG

$2.0B

Neogenomics Inc NEO

$963.2M

Grail Inc GRAL

$2.1B

Twist Bioscience TWST

$2.9B

Caredx CDNA

$889.1M

Frequently Asked Questions

What is Opko Health's annual revenue?

Opko Health (OPK) reported $606.9M in total revenue for fiscal year 2025. This represents a -14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Opko Health's revenue growing?

Opko Health (OPK) revenue declined by 14.9% year-over-year, from $713.1M to $606.9M in fiscal year 2025.

Is Opko Health profitable?

No, Opko Health (OPK) reported a net income of -$225.7M in fiscal year 2025, with a net profit margin of -37.2%.

What is Opko Health's EBITDA?

Opko Health (OPK) had EBITDA of -$25.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Opko Health have?

As of fiscal year 2025, Opko Health (OPK) had $364.4M in cash and equivalents against $2.3M in long-term debt.

What is Opko Health's gross margin?

Opko Health (OPK) had a gross margin of 33.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Opko Health's operating margin?

Opko Health (OPK) had an operating margin of -19.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Opko Health's net profit margin?

Opko Health (OPK) had a net profit margin of -37.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Opko Health's return on equity (ROE)?

Opko Health (OPK) has a return on equity of -17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Opko Health's free cash flow?

Opko Health (OPK) generated -$190.8M in free cash flow during fiscal year 2025. This represents a 8.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Opko Health's operating cash flow?

Opko Health (OPK) generated -$178.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Opko Health's total assets?

Opko Health (OPK) had $1.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Opko Health's capital expenditures?

Opko Health (OPK) invested $12.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Opko Health spend on research and development?

Opko Health (OPK) invested $124.0M in research and development during fiscal year 2025.

Does Opko Health buy back shares?

Yes, Opko Health (OPK) spent $47.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Opko Health have outstanding?

Opko Health (OPK) had 759M shares outstanding as of fiscal year 2025.

What is Opko Health's current ratio?

Opko Health (OPK) had a current ratio of 3.97 as of fiscal year 2025, which is generally considered healthy.

What is Opko Health's debt-to-equity ratio?

Opko Health (OPK) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Opko Health's return on assets (ROA)?

Opko Health (OPK) had a return on assets of -11.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Opko Health's cash runway?

Based on fiscal year 2025 data, Opko Health (OPK) had $364.4M in cash against an annual operating cash burn of $178.5M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Opko Health's Piotroski F-Score?

Opko Health (OPK) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Opko Health's earnings high quality?

Opko Health (OPK) has an earnings quality ratio of 0.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Opko Health?

Opko Health (OPK) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.